Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote & News

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 443 776 3133

Fax: 443 288 4420

Website: www.processapharmaceuticals.com

Address:

7380 Coca Cola Drive, Suite 106, Hanover, United States

Goldengun23 Mar. 17 at 6:29 PM

$PCSA cmon give us a moonshot to $40 one time

0 · Reply

smartmoney43 Mar. 16 at 8:14 PM

$PCSA 😍😍

0 · Reply

Shallu Mar. 16 at 4:11 PM

$PCSA huge buy signal……?☕️📈

0 · Reply

SDBiotechInvestor Mar. 16 at 4:09 PM

$PCSA - another strong day. News should be imminent.

0 · Reply

SuperGreenToday Mar. 13 at 10:53 PM

$PCSA

0 · Reply

SDBiotechInvestor Mar. 13 at 3:30 PM

$PCSA - Kind of get a vibe some sort of news is coming premarket Monday.

1 · Reply

TheDrunkTrader69 Mar. 12 at 5:06 PM

$PCSA adding

0 · Reply

SDBiotechInvestor Mar. 11 at 6:04 PM

$PCSA - Chart looks ready to "moon." Perhaps with the help of our 13% crypto holder Dreyfus.

0 · Reply

SDBiotechInvestor Mar. 11 at 3:29 PM

$PCSA - No matter anyone's opinion on the merits of this company you have to admit the stock grinding up with little to no selling is bullish ahead of any interim cancer data or crypto based announcement.

0 · Reply

TheDrunkTrader69 Mar. 11 at 1:20 PM

$PCSA It will do nothing until it does, but when it does your to late. 0 to 100mph this stock will go. Im waiting patiently.

0 · Reply

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:15 AM EST - 2 months ago

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Dec 17, 2025, 1:10 PM EST - 3 months ago

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Dec 17, 2025, 8:00 AM EST - 3 months ago

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Nov 5, 2025, 9:15 AM EST - 4 months ago

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Aug 7, 2025, 8:30 AM EDT - 7 months ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Jul 1, 2025, 9:00 AM EDT - 9 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Jun 17, 2025, 12:26 PM EDT - 9 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 9:00 AM EDT - 9 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 13, 2025, 8:00 AM EDT - 9 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

May 30, 2025, 9:00 AM EDT - 10 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Feb 7, 2025, 8:00 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 5:17 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

May 6, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Mar 25, 2024, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Feb 21, 2024, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 14, 2024, 1:00 PM EST - 2 years ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 6, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 1, 2024, 4:22 PM EST - 2 years ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 2 years ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 25, 2024, 11:29 AM EST - 2 years ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 19, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 18, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 2, 2024, 5:06 PM EST - 2 years ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Dec 19, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 13, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

May 22, 2023, 8:05 AM EDT - 3 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Apr 28, 2023, 8:15 AM EDT - 3 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Mar 31, 2023, 4:14 PM EDT - 3 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 3 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Goldengun23 Mar. 17 at 6:29 PM

$PCSA cmon give us a moonshot to $40 one time

0 · Reply

smartmoney43 Mar. 16 at 8:14 PM

$PCSA 😍😍

0 · Reply

Shallu Mar. 16 at 4:11 PM

$PCSA huge buy signal……?☕️📈

0 · Reply

SDBiotechInvestor Mar. 16 at 4:09 PM

$PCSA - another strong day. News should be imminent.

0 · Reply

SuperGreenToday Mar. 13 at 10:53 PM

$PCSA

0 · Reply

SDBiotechInvestor Mar. 13 at 3:30 PM

$PCSA - Kind of get a vibe some sort of news is coming premarket Monday.

1 · Reply

TheDrunkTrader69 Mar. 12 at 5:06 PM

$PCSA adding

0 · Reply

SDBiotechInvestor Mar. 11 at 6:04 PM

$PCSA - Chart looks ready to "moon." Perhaps with the help of our 13% crypto holder Dreyfus.

0 · Reply

SDBiotechInvestor Mar. 11 at 3:29 PM

0 · Reply

TheDrunkTrader69 Mar. 11 at 1:20 PM

$PCSA It will do nothing until it does, but when it does your to late. 0 to 100mph this stock will go. Im waiting patiently.

0 · Reply

Jwa68 Mar. 10 at 2:38 AM

$PCSA What happened David? I thought a man's word is supposed to be his bond?

0 · Reply

Jwa68 Mar. 9 at 3:06 AM

$PCSA Over-promise and under-deliver" occurs when expectations exceed reality, causing damaged trust and reputation. Driven by people-pleasing or unrealistic optimism, it leads to missed deadlines and poor quality, particularly in business relationships. It also leads to value destruction and shareholder losses.

0 · Reply

Zing43 Mar. 9 at 1:45 AM

$PCSA

0 · Reply

Jwa68 Mar. 8 at 12:11 PM

$PCSA

0 · Reply

StockLady1970 Mar. 8 at 2:23 AM

$PCSA Watching the below video if you fast forward to 10:17 David Young states the company has 5 assets in drug development with each having a billion in market potential. Does anyone know what happened to all these drugs? I am trying to understand if the drugs are gone? Did they fail? What happened? Seems odd to me. Why would 5 total drugs in development be gone except for one? I can't find anything besides the failed license with that Intact company and the cancer drug in litigation with the owner. Is there anyone who knows? Video below of David Young speaking on the 5 drugs. Are the other drugs still around? Is the company doing anything with them? Maybe I missed something. Seems very confusing. https://www.nasdaq.com/videos/processa-pharmaceuticals-rings-nasdaq-stock-market-closing-bell

0 · Reply

StockLady1970 Mar. 7 at 6:50 PM

$PCSA does anyone know when the multiple phase 3 trials start? I want to buy the stock, just concerned they are years behind. Should I be? David Young said 2023, it is 2026. What happened? Anyone know? "In 2022, our focus continues to be developing our pipeline of drugs to obtain data that would allow us to initiate multiple Phase 3 trials in 2023." https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/63/processa-pharmaceuticals-ceo-dr-david-young-issues-letter

1 · Reply

StockLady1970 Mar. 7 at 6:41 PM

$PCSA does anyone know why David Young spoke at this conference? Outside of this conference press release all I have seen from him online is stock promotion videos and promises of 5 drugs worth billions yet the company can barely cover payroll. I am confused. Anyone know? https://orphandrugsus.com/speakers/

0 · Reply

Shallu Mar. 6 at 9:16 PM

$PCSA Im really waiting at least 10$

0 · Reply

SDBiotechInvestor Mar. 6 at 5:02 PM

$PCSA - For anyone here concerned about the current cash left. Alexandre Dreyfus now owns 13% of the company and recently bought $200,000 worth of stock @$2.30 in Feb.

2 · Reply

Jwa68 Mar. 6 at 1:31 PM

$PCSA How much cash can possibly be left based on their own public filings. One has to wonder, what are the ethical and moral considerations for a company running a cancer trial and placing patients on a drug when they may not be able to complete the trial due to lack of capital? This is life and death for these people. 6422 is an amazing drug. Hard to not conclude David Young has been a poor steward of it, leqding to delay after delay, millions wasted, and a lawsuit with its owner. Just my personal opinion habing witnessed it forst hand and been financially harmed by it. DYDD...

1 · Reply

aletz Mar. 6 at 9:13 AM

$PCSA https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk122026/ Featured in the AI Catalyst Scanner for the second week of March. This scanner integrates advanced AI research with machine learning patterns, leveraging over a decade of data alongside catalyst-driven quality and technical indicators. Disclaimer: BSI score is a rating derived from combined AI and ML models and does not guarantee specific outcomes.

0 · Reply

Goldengun23 Mar. 5 at 11:22 PM

$PCSA looks like they’ve updated their website significantly

0 · Reply

Market Cap	6.68M
Revenue (ttm)	0.00
Net Income (ttm)	-11.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,111
Avg Vol	61,400
Day's Range	N/A - N/A
Shares Out	2.27M
Stochastic %K	80%
Beta	1.05
Analysts	Sell
Price Target	$25.00